Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Gracell's BCMA/CD19 CAR-T Starts China Trial for Non-Hodgkin's Lymphoma

publication date: Feb 17, 2022

Suzhou Gracell Biotechnologies reported a China Phase I trial of its dual targeting autologous CAR-T candidate has begun in patients with B-cell non-Hodgkin's lymphoma. GC012F, which targets B cell maturation antigen (BCMA) and CD19, uses Gracell's FasTCAR technology for one-day manufacturing of the CAR-T. The Phase I investigator-initiated trial (IIT) is the first study evaluating GC012F as a therapy for relapsed or refractory B-NHL. Another China IIT investigating the CAR-T candidate in patients with relapsed/refractory multiple myeloma is already underway. More details....

Stock Symbol: (NSDQ: GRCL)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.